1. Gerber JE, Cawthon B. Overdose and death with olanzapine: two case reports. Am J Forensic Med Pathol. 2000 Sep;21(3):249-51. doi: 10.1097/00000433-200009000-00013. PMID: 10990286. [cited 2022 June 27]
2. Report from US Justice Dept #09-038: Eli Lilly amd Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa published 2009 [cited 2022 June 27]
3. FDA ZYPREXA (Olanzapine) label [cited 2022 June 27]
4. Alicia Ruelaz Maher, Margaret Maglione, Steven Bagley, Marika Suttorp, Jian-Hui Hu, Brett Ewing, Zhen Wang, Martha Timmer, David Sultzer, Paul G. Shekelle. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis. JAMA, 2011; 306 (12): 1359-1369 [cited 2022 June 27]
5. Aucoin M, LaChance L, Clouthier SN, Cooley K. Dietary modification in the treatment of schizophrenia spectrum disorders: A systematic review. World J Psychiatry. 2020 Aug 19;10(8):187-201. doi: 10.5498/wjp.v10.i8.187. PMID: 32874956; PMCID: PMC7439299. [cited 2022 June 27]
6. Aucoin M, LaChance L, Cooley K, Kidd S. Diet and Psychosis: A Scoping Review. Neuropsychobiology. 2020;79(1):20-42. doi: 10.1159/000493399. Epub 2018 Oct 25. PMID: 30359969. [cited 2022 June 27]
7. Głąbska D, Guzek D, Groele B, Gutkowska K. Fruit and Vegetable Intake and Mental Health in Adults: A Systematic Review. Nutrients. 2020;12(1):115. Published 2020 Jan 1. doi:10.3390/nu12010115 [cited 2022 June 27]
8. Ho BC, Andreasen NC, Ziebell S et al., “Long-term Antipsychotic Treatment and Brain Volume” JAMA [online] Feb 2011 [cited 2022 June 27]
9. Włodarczyk A, Wiglusz MS, Cubała WJ. Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment. Med Hypotheses. 2018 Sep;118:74-77. doi: 10.1016/j.mehy.2018.06.022. Epub 2018 Jun 20. PMID: 30037619. [cited 2022 June 27]
10. Rathod S, Phiri P, Kingdon D. Cognitive behavioral therapy for schizophrenia. Psychiatr Clin North Am. 2010 Sep;33(3):527-36. doi: 10.1016/j.psc.2010.04.009. PMID: 20599131. [cited 2022 June 27]
11. Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res. 2016;176:23–35. [cited 2022 June 27]
12. Ganguly P, Soliman A, Moustafa AA. Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. Front Public Health. 2018;6:166. Published 2018 Jun 7. doi:10.3389/fpubh.2018.00166 [cited 2021 Dec 7]
13. Moore E, Mancuso SG, Slade T, Galletly C, Castle DJ. The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis. Aust N Z J Psychiatry. 2012 Sep;46(9):864-78. doi: 10.1177/0004867412443900. Epub 2012 Apr 3. PMID: 22472772. [cited 2021 Dec 7]
14. Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, Leweke FM, Strube W, Hoch E. Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):403-412. doi: 10.1007/s00406-019-01068-z. Epub 2019 Sep 28. PMID: 31563981.[cited 2021 Dec 7]
15. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci. 2008;45(1):19-25. PMID: 18587166. [cited 2021 Dec 7]
16. Assisi A, Banzi R, Buonocore C, Capasso F, Di Muzio V, Michelacci F, Renzo D, Tafuri G, Trotta F, Vitocolonna M, Garattini S. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol. 2006 Nov;21(6):319-36. doi: 10.1097/01.yic.0000224790.98534.11. PMID: 17012979. [cited 2021 Dec 7]
17. Hoenders HJR, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, de Jong JTVM. Natural Medicines for Psychotic Disorders: A Systematic Review. J Nerv Ment Dis. 2018;206(2):81-101. doi:10.1097/NMD.0000000000000782 [cited 2021 Dec 7]
18. Hedges DW, Woon FL, Hoopes SP. Caffeine-induced psychosis. CNS Spectr. 2009 Mar;14(3):127-9. doi: 10.1017/s1092852900020101. PMID: 19407709.[cited 2021 Dec 7]
19. Levy MI, Davis BM, Mohs RC, Trigos GC, Mathé AA, Davis KL. (1983) Gamma-hydroxybutyrate in the treatment of schizophrenia. Psychiatry Res 9:1–8. [cited 2021 Dec 7]
20. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001 Apr 30;49(3):243-51. doi: 10.1016/s0920-9964(00)00083-9. PMID: 11356585. [cited 2021 Dec 7]
21. Morris JA. Schizophrenia, bacterial toxins and the genetics of redundancy. Med Hypotheses. 1996 Apr;46(4):362-6. doi: 10.1016/s0306-9877(96)90188-7. PMID: 8733166. [cited 2021 Dec 7]
22. Al Osman M, Yang F, Massey IY. Exposure routes and health effects of heavy metals on children. Biometals. 2019 Aug;32(4):563-573. doi: 10.1007/s10534-019-00193-5. Epub 2019 Apr 2. PMID: 30941546.[cited 2021 Dec 7]
23. Ergün C, Urhan M, Ayer A. A review on the relationship between gluten and schizophrenia: Is gluten the cause? Nutr Neurosci. 2018 Sep;21(7):455-466. doi: 10.1080/1028415X.2017.1313569. Epub 2017 Apr 9. PMID: 28393621. [cited 2022 June 27]
24. Leucht S, Schneider-Thoma J, Burschinski A, Peter N, Wang D, Dong S, Huhn M, Nikolakopoulou A, Salanti G, Davis JM. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World Psychiatry. 2023 Jun;22(2):315-324. doi: 10.1002/wps.21089. PMID: 37159349; PMCID: PMC10168166. [cited 2025 Sept 2]
25. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. PMID: 31860457; PMCID: PMC7029416. [cited 2025 Sept 2]
26. Morant N, Long M, Jayacodi S, Cooper R, Akther-Robertson J, Stansfeld J, Horowitz M, Priebe S, Moncrieff J. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial. EClinicalMedicine. 2023 Sep 28;64:102135. doi: 10.1016/j.eclinm.2023.102135. PMID: 37936655; PMCID: PMC10626156. [cited 2025 Sept 2]